Cytokinetics pharmaceuticals news
WebPipeline - Cytokinetics A pipeline powered by passion pipeline Research Pre-Clinical Phase 1 Phase 2 Phase 3 CARDIAC MUSCLE Omecamtiv Mecarbil (Heart Failure) … WebAug 2, 2024 · About Cytokinetics. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and ...
Cytokinetics pharmaceuticals news
Did you know?
WebNov 3, 2024 · Cytokinetics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $2.52 million for the quarter ended September 2024, … WebMar 31, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential …
WebDec 9, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. WebApr 13, 2024 · In other Cytokinetics news, CEO Robert I. Blum sold 12,500 shares of the company’s stock in a transaction on Tuesday, March 28th. The stock was sold at an average price of $35.05, for a total transaction of $438,125.00. ... China Universal Asset Management Co. Ltd. Reduces Position in Madrigal Pharmaceuticals, Inc.
Web12 hours ago · Cytokinetics (CYTK) In a report released yesterday, Madhu Kumar from Goldman Sachs maintained a Buy rating on Cytokinetics. The company’s shares closed last Thursday at $35.93, close to its 52 ... Web2 days ago · Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of ...
WebApr 10, 2024 · Kumar covers the Healthcare sector, focusing on stocks such as Cytokinetics, Syndax Pharmaceuticals, and Fulcrum Therapeutics. According to TipRanks , Kumar has an average return of 17.8% and a 49 ...
WebMar 4, 2024 · After the downgrade, the consensus from Cytokinetics' eleven analysts is for revenues of US$25m in 2024, which would reflect a painful 65% decline in sales compared to the last year of performance ... img protectWebFeb 4, 2024 · Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and … imgpts np.int32 imgpts .reshape -1 2WebApr 11, 2024 · Cytokinetics (NASDAQ:CYTK) has a market capitalization of $3.48 billion and generates $94.59 million in revenue each year. The biopharmaceutical company … list of pokemon packsWebJan 11, 2024 · ClinicalTrials.gov Identifier: NCT05186818 Recruitment Status : Recruiting First Posted : January 11, 2024 Last Update Posted : March 13, 2024 See Contacts and Locations View this study on Beta.ClinicalTrials.gov Sponsor: Cytokinetics Collaborator: Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. Information provided by (Responsible Party): imgpv2 implements what featureWebJan 7, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media Cytokinetics’ unparalleled expertise … list of pokemon not in scarlet violetWebApr 10, 2024 · Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. About the company Rewards Revenue is forecast to grow 46.65% per year Risk Analysis Negative shareholders equity img providers columbia missouriWeb16 rows · Mar 27, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused … img punisher